MAP2K1 and melanoma: Encorafenib is a small-molecule ATP-competitive BRAF inhibitor.27 In the phase 3 COLUMBUS trial (NCT01909453), co-administration of standard-dose encorafenib 450 mg once daily (QD) with the MEK1/2 inhibitor binimetinib 45 mg twice daily (BID) demonstrated efficacy in patients with BRAF V600-mutant melanoma with generally reversible and manageable adverse events (AEs) and a relatively low rate of treatment discontinuation due to AEs (16%–18%3,5; the most common were alanine aminotransferase, aspartate aminotransferase, blood creatinine, headache, and rash).3,5